[Form 4] Eyenovia, Inc. Insider Trading Activity

Q: How much cash does Nurix Therapeutics (NRIX) have after Q2 2025?

Nurix reported $485.8 million in cash, cash equivalents and marketable securities as of 31 May 2025.

Q: What drove the 264% revenue increase for NRIX in Q2 2025?

Revenue growth was primarily due to a $30 million license fee from Sanofi and higher ongoing collaboration revenue.

Q: What is Nurix’s current cash burn rate?

Operating activities used $124.2 million in cash over six months, implying roughly $20 million per month.

Q: Did Nurix post a profit in Q2 2025?

No. The company recorded a net loss of $43.5 million (-$0.52 per share) for the quarter.

Q: How many shares of NRIX are outstanding?

As of 31 May 2025, Nurix had 76,449,355 common shares outstanding.

Q: What milestones could NRIX receive from its partners?

Potential future milestone payments total up to ~$1.8 billion from Gilead, ~$949 million from Sanofi, and ~$3.4 billion from Pfizer, plus royalties.

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. (Nasdaq: NRIX) – Fiscal Q2 2025 10-Q highlights

Revenue inflection: Total Q2 revenue jumped to $44.1 million (up 264% YoY) driven by a $30 million license fee from Sanofi and higher collaboration revenue from existing partnerships with Sanofi, Gilead and Pfizer.
Operating costs accelerate: R&D expense expanded 60% YoY to $78.1 million as the company advanced clinical programs (NX-5948, NX-2127, NX-1607) and DAC discovery work; G&A rose 22% to $14.3 million.
Loss narrows modestly for the quarter: Net loss was $43.5 million (-$0.52 per share) versus $44.5 million (-$0.71) a year ago, helped by the one-time license payment and a larger share count. For the six-month period, however, the loss widened to $99.8 million.
Cash runway: Cash, cash equivalents and marketable securities totaled $485.8 million at 31 May 2025, down from $609.6 million at FY-end. Operating cash burn reached $124.2 million in the first half. Management believes existing liquidity funds operations for at least 12 months.
Collaboration momentum: • Gilead extended the research term by two years, triggering a $15 million payment.
• Sanofi exercised two target license options, providing $30 million.
• Pfizer collaboration produced $10 million in research milestones to date.
Equity activity: 76.4 million shares outstanding after ATM issuances; stockholders’ equity fell to $447.6 million from $527.0 million on higher deficit.

Overall, Nurix continues to monetize its DEL-AI platform through partner payments while accelerating internal R&D, resulting in higher cash burn and sustained losses.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) – Highlights del 10-Q del secondo trimestre fiscale 2025

Incremento dei ricavi: I ricavi totali del secondo trimestre sono saliti a 44,1 milioni di dollari (in aumento del 264% su base annua), grazie a una licenza da 30 milioni di dollari concessa da Sanofi e a maggiori ricavi da collaborazioni con Sanofi, Gilead e Pfizer.
Accelerazione dei costi operativi: Le spese di R&S sono aumentate del 60% su base annua, raggiungendo 78,1 milioni di dollari, mentre la società ha portato avanti i programmi clinici (NX-5948, NX-2127, NX-1607) e le attività di scoperta DAC; le spese generali e amministrative sono cresciute del 22%, arrivando a 14,3 milioni di dollari.
Perdita trimestrale leggermente ridotta: La perdita netta è stata di 43,5 milioni di dollari (-0,52 dollari per azione) rispetto a 44,5 milioni (-0,71 dollari per azione) dell’anno precedente, favorita dal pagamento una tantum della licenza e da un maggior numero di azioni in circolazione. Tuttavia, nel periodo di sei mesi la perdita si è ampliata a 99,8 milioni di dollari.
Liquidità disponibile: Al 31 maggio 2025, la liquidità, equivalenti di cassa e titoli negoziabili ammontavano a 485,8 milioni di dollari, in calo rispetto ai 609,6 milioni di fine anno fiscale. Il burn rate operativo di cassa ha raggiunto i 124,2 milioni nella prima metà dell’anno. La direzione ritiene che la liquidità attuale sosterrà le operazioni per almeno 12 mesi.
Slancio nelle collaborazioni: • Gilead ha esteso il termine di ricerca di due anni, attivando un pagamento di 15 milioni di dollari.
• Sanofi ha esercitato due opzioni di licenza su target, per un valore di 30 milioni di dollari.
• La collaborazione con Pfizer ha generato finora 10 milioni di dollari in milestone di ricerca.
Attività azionaria: 76,4 milioni di azioni in circolazione dopo emissioni ATM; il patrimonio netto degli azionisti è sceso a 447,6 milioni di dollari dai 527,0 milioni per un aumento del deficit.

In generale, Nurix continua a monetizzare la sua piattaforma DEL-AI attraverso pagamenti da partner, mentre accelera la R&S interna, con conseguente aumento del burn rate di cassa e perdite sostenute.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) – Destacados del 10-Q del segundo trimestre fiscal 2025

Incremento de ingresos: Los ingresos totales del segundo trimestre aumentaron a 44,1 millones de dólares (un 264% más interanual) impulsados por una cuota de licencia de 30 millones de dólares de Sanofi y mayores ingresos por colaboraciones con Sanofi, Gilead y Pfizer.
Aceleración de costos operativos: Los gastos en I+D crecieron un 60% interanual hasta 78,1 millones de dólares, mientras la compañía avanzó en programas clínicos (NX-5948, NX-2127, NX-1607) y trabajos de descubrimiento DAC; los gastos generales y administrativos aumentaron un 22% hasta 14,3 millones de dólares.
Pérdida trimestral ligeramente reducida: La pérdida neta fue de 43,5 millones de dólares (-0,52 dólares por acción) frente a 44,5 millones (-0,71) del año anterior, favorecida por el pago único de la licencia y un mayor número de acciones. Sin embargo, en el período de seis meses la pérdida se amplió a 99,8 millones de dólares.
Liquidez disponible: Al 31 de mayo de 2025, el efectivo, equivalentes y valores negociables sumaban 485,8 millones de dólares, por debajo de los 609,6 millones al cierre del ejercicio. El consumo operativo de efectivo alcanzó 124,2 millones en la primera mitad. La dirección considera que la liquidez existente financiará las operaciones al menos por 12 meses.
Impulso en colaboraciones: • Gilead extendió el plazo de investigación dos años más, activando un pago de 15 millones.
• Sanofi ejerció dos opciones de licencia para objetivos, aportando 30 millones.
• La colaboración con Pfizer ha generado hasta la fecha 10 millones en hitos de investigación.
Actividad accionaria: 76,4 millones de acciones en circulación tras emisiones ATM; el patrimonio neto de los accionistas cayó a 447,6 millones desde 527,0 millones por un mayor déficit.

En general, Nurix continúa monetizando su plataforma DEL-AI mediante pagos de socios, mientras acelera la I+D interna, resultando en un mayor consumo de efectivo y pérdidas sostenidas.

Nurix Therapeutics, Inc. (Nasdaq : NRIX) – Points clés du 10-Q du deuxième trimestre fiscal 2025

Inflection des revenus : Le chiffre d'affaires total du T2 a grimpé à 44,1 millions de dollars (en hausse de 264 % sur un an) grâce à une redevance de licence de 30 millions de dollars de Sanofi et à une augmentation des revenus de collaboration avec Sanofi, Gilead et Pfizer.
Accélération des coûts d'exploitation : Les dépenses de R&D ont augmenté de 60 % sur un an pour atteindre 78,1 millions de dollars alors que la société a fait progresser les programmes cliniques (NX-5948, NX-2127, NX-1607) et les travaux de découverte DAC ; les frais généraux et administratifs ont augmenté de 22 % pour atteindre 14,3 millions de dollars.
Perte trimestrielle légèrement réduite : La perte nette s’est élevée à 43,5 millions de dollars (-0,52 $ par action) contre 44,5 millions (-0,71 $) un an plus tôt, aidée par le paiement unique de licence et un nombre d’actions plus élevé. Cependant, sur six mois, la perte s’est creusée à 99,8 millions de dollars.
Trésorerie disponible : Au 31 mai 2025, la trésorerie, les équivalents de trésorerie et les titres négociables s’élevaient à 485,8 millions de dollars, en baisse par rapport à 609,6 millions à la fin de l’exercice. La consommation de trésorerie d’exploitation a atteint 124,2 millions au premier semestre. La direction estime que la liquidité existante finance les opérations pour au moins 12 mois.
Élan des collaborations : • Gilead a prolongé la durée de recherche de deux ans, déclenchant un paiement de 15 millions de dollars.
• Sanofi a exercé deux options de licence sur cibles, apportant 30 millions de dollars.
• La collaboration avec Pfizer a généré à ce jour 10 millions de dollars de jalons de recherche.
Activité sur les actions : 76,4 millions d’actions en circulation après émissions ATM ; les capitaux propres des actionnaires ont chuté à 447,6 millions de dollars contre 527,0 millions en raison d’un déficit accru.

Dans l’ensemble, Nurix continue de monétiser sa plateforme DEL-AI grâce aux paiements de ses partenaires tout en accélérant sa R&D interne, ce qui entraîne une augmentation de la consommation de trésorerie et des pertes soutenues.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) – Highlights des 10-Q für das zweite Fiskalquartal 2025

Umsatzanstieg: Der Gesamtumsatz im zweiten Quartal stieg auf 44,1 Millionen US-Dollar (plus 264 % im Jahresvergleich), angetrieben durch eine 30 Millionen US-Dollar Lizenzgebühr von Sanofi sowie höhere Kooperationsumsätze mit Sanofi, Gilead und Pfizer.
Beschleunigte Betriebskosten: Die F&E-Ausgaben stiegen im Jahresvergleich um 60 % auf 78,1 Millionen US-Dollar, da das Unternehmen klinische Programme (NX-5948, NX-2127, NX-1607) und DAC-Entdeckungsarbeiten vorantrieb; die allgemeinen Verwaltungsaufwendungen stiegen um 22 % auf 14,3 Millionen US-Dollar.
Verlust im Quartal leicht verringert: Der Nettoverlust betrug 43,5 Millionen US-Dollar (-0,52 US-Dollar je Aktie) gegenüber 44,5 Millionen (-0,71) im Vorjahr, begünstigt durch die einmalige Lizenzzahlung und eine höhere Aktienanzahl. Für den Sechsmonatszeitraum weitete sich der Verlust jedoch auf 99,8 Millionen US-Dollar aus.
Cash-Runway: Zum 31. Mai 2025 beliefen sich Barmittel, Zahlungsmitteläquivalente und handelbare Wertpapiere auf 485,8 Millionen US-Dollar, gegenüber 609,6 Millionen zum Geschäftsjahresende. Der operative Cash-Burn erreichte in der ersten Jahreshälfte 124,2 Millionen. Das Management geht davon aus, dass die vorhandene Liquidität die Geschäftstätigkeit mindestens 12 Monate finanziert.
Kooperationsdynamik: • Gilead verlängerte die Forschungsphase um zwei Jahre und löste eine Zahlung von 15 Millionen US-Dollar aus.
• Sanofi übte zwei Ziel-Lizenzoptionen aus und brachte 30 Millionen US-Dollar ein.
• Die Zusammenarbeit mit Pfizer erzielte bisher 10 Millionen US-Dollar an Forschungsmeilensteinen.
Aktienaktivität: Nach ATM-Emissionen sind 76,4 Millionen Aktien ausstehend; das Eigenkapital der Aktionäre sank aufgrund eines höheren Defizits von 527,0 Millionen auf 447,6 Millionen US-Dollar.

Insgesamt monetarisiert Nurix weiterhin seine DEL-AI-Plattform durch Partnerzahlungen, während die interne F&E beschleunigt wird, was zu einem höheren Cash-Burn und anhaltenden Verlusten führt.

Positive

$30 million license payment from Sanofi plus collaboration fees lifted quarterly revenue to $44.1 million.
Research term extension by Gilead delivered $15 million and extends partnership visibility to 2026.
Year-end liquidity remains strong at $485.8 million, providing at least 12 months operating runway.
Partnership portfolio could yield up to $6.1 billion in future milestones and tiered royalties.

Negative

Operating cash burn reached $124.2 million in six months, up 52% YoY.
R&D expenses climbed 60% YoY, widening the six-month net loss to $99.8 million.
Cash and marketable securities declined by $123.8 million since November 2024.
Share count dilution from equity financings increased outstanding shares to 76.4 million.

Insights

TL;DR – License revenue boosts top line but cash burn still heavy; neutral net impact.

Nurix’s Q2 print showcases the value of its collaboration portfolio: a $30 million Sanofi license and $1.6 million from a Gilead extension delivered a 264% revenue surge. Yet R&D outlays jumped 60% as three proprietary clinical assets and multiple DAC projects advance. Cash reserves of $485.8 million equal roughly ~18-20 months of current burn; management projects ≥12 months runway, but additional financing is likely before commercial revenues. No new clinical efficacy data were disclosed in this filing, so fundamental valuation hinges on upcoming readouts. Overall, the one-off revenue is positive but not thesis-changing; the quarter is best viewed as operationally neutral.

TL;DR – Partnerships de-risk pipeline; dilution risk persists.

The Sanofi and Gilead transactions validate Nurix’s DEL-AI platform and add non-dilutive cash, but they do not offset the ~$200 million annualized cash burn. Share count rose ~18% YoY through the April 2024 public offering and ATM programs, and further equity raises remain probable. From a portfolio standpoint, the stock offers upside optionality on clinical success with manageable near-term liquidity risk, yet investors must tolerate ongoing dilution and binary trial outcomes. I classify the filing as neutral/steady: constructive on strategic progress, offset by financial strain.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) – Highlights del 10-Q del secondo trimestre fiscale 2025

Incremento dei ricavi: I ricavi totali del secondo trimestre sono saliti a 44,1 milioni di dollari (in aumento del 264% su base annua), grazie a una licenza da 30 milioni di dollari concessa da Sanofi e a maggiori ricavi da collaborazioni con Sanofi, Gilead e Pfizer.
Accelerazione dei costi operativi: Le spese di R&S sono aumentate del 60% su base annua, raggiungendo 78,1 milioni di dollari, mentre la società ha portato avanti i programmi clinici (NX-5948, NX-2127, NX-1607) e le attività di scoperta DAC; le spese generali e amministrative sono cresciute del 22%, arrivando a 14,3 milioni di dollari.
Perdita trimestrale leggermente ridotta: La perdita netta è stata di 43,5 milioni di dollari (-0,52 dollari per azione) rispetto a 44,5 milioni (-0,71 dollari per azione) dell’anno precedente, favorita dal pagamento una tantum della licenza e da un maggior numero di azioni in circolazione. Tuttavia, nel periodo di sei mesi la perdita si è ampliata a 99,8 milioni di dollari.
Liquidità disponibile: Al 31 maggio 2025, la liquidità, equivalenti di cassa e titoli negoziabili ammontavano a 485,8 milioni di dollari, in calo rispetto ai 609,6 milioni di fine anno fiscale. Il burn rate operativo di cassa ha raggiunto i 124,2 milioni nella prima metà dell’anno. La direzione ritiene che la liquidità attuale sosterrà le operazioni per almeno 12 mesi.
Slancio nelle collaborazioni: • Gilead ha esteso il termine di ricerca di due anni, attivando un pagamento di 15 milioni di dollari.
• Sanofi ha esercitato due opzioni di licenza su target, per un valore di 30 milioni di dollari.
• La collaborazione con Pfizer ha generato finora 10 milioni di dollari in milestone di ricerca.
Attività azionaria: 76,4 milioni di azioni in circolazione dopo emissioni ATM; il patrimonio netto degli azionisti è sceso a 447,6 milioni di dollari dai 527,0 milioni per un aumento del deficit.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) – Destacados del 10-Q del segundo trimestre fiscal 2025

Incremento de ingresos: Los ingresos totales del segundo trimestre aumentaron a 44,1 millones de dólares (un 264% más interanual) impulsados por una cuota de licencia de 30 millones de dólares de Sanofi y mayores ingresos por colaboraciones con Sanofi, Gilead y Pfizer.
Aceleración de costos operativos: Los gastos en I+D crecieron un 60% interanual hasta 78,1 millones de dólares, mientras la compañía avanzó en programas clínicos (NX-5948, NX-2127, NX-1607) y trabajos de descubrimiento DAC; los gastos generales y administrativos aumentaron un 22% hasta 14,3 millones de dólares.
Pérdida trimestral ligeramente reducida: La pérdida neta fue de 43,5 millones de dólares (-0,52 dólares por acción) frente a 44,5 millones (-0,71) del año anterior, favorecida por el pago único de la licencia y un mayor número de acciones. Sin embargo, en el período de seis meses la pérdida se amplió a 99,8 millones de dólares.
Liquidez disponible: Al 31 de mayo de 2025, el efectivo, equivalentes y valores negociables sumaban 485,8 millones de dólares, por debajo de los 609,6 millones al cierre del ejercicio. El consumo operativo de efectivo alcanzó 124,2 millones en la primera mitad. La dirección considera que la liquidez existente financiará las operaciones al menos por 12 meses.
Impulso en colaboraciones: • Gilead extendió el plazo de investigación dos años más, activando un pago de 15 millones.
• Sanofi ejerció dos opciones de licencia para objetivos, aportando 30 millones.
• La colaboración con Pfizer ha generado hasta la fecha 10 millones en hitos de investigación.
Actividad accionaria: 76,4 millones de acciones en circulación tras emisiones ATM; el patrimonio neto de los accionistas cayó a 447,6 millones desde 527,0 millones por un mayor déficit.

En general, Nurix continúa monetizando su plataforma DEL-AI mediante pagos de socios, mientras acelera la I+D interna, resultando en un mayor consumo de efectivo y pérdidas sostenidas.

Nurix Therapeutics, Inc. (Nasdaq : NRIX) – Points clés du 10-Q du deuxième trimestre fiscal 2025

Inflection des revenus : Le chiffre d'affaires total du T2 a grimpé à 44,1 millions de dollars (en hausse de 264 % sur un an) grâce à une redevance de licence de 30 millions de dollars de Sanofi et à une augmentation des revenus de collaboration avec Sanofi, Gilead et Pfizer.
Accélération des coûts d'exploitation : Les dépenses de R&D ont augmenté de 60 % sur un an pour atteindre 78,1 millions de dollars alors que la société a fait progresser les programmes cliniques (NX-5948, NX-2127, NX-1607) et les travaux de découverte DAC ; les frais généraux et administratifs ont augmenté de 22 % pour atteindre 14,3 millions de dollars.
Perte trimestrielle légèrement réduite : La perte nette s’est élevée à 43,5 millions de dollars (-0,52 $ par action) contre 44,5 millions (-0,71 $) un an plus tôt, aidée par le paiement unique de licence et un nombre d’actions plus élevé. Cependant, sur six mois, la perte s’est creusée à 99,8 millions de dollars.
Trésorerie disponible : Au 31 mai 2025, la trésorerie, les équivalents de trésorerie et les titres négociables s’élevaient à 485,8 millions de dollars, en baisse par rapport à 609,6 millions à la fin de l’exercice. La consommation de trésorerie d’exploitation a atteint 124,2 millions au premier semestre. La direction estime que la liquidité existante finance les opérations pour au moins 12 mois.
Élan des collaborations : • Gilead a prolongé la durée de recherche de deux ans, déclenchant un paiement de 15 millions de dollars.
• Sanofi a exercé deux options de licence sur cibles, apportant 30 millions de dollars.
• La collaboration avec Pfizer a généré à ce jour 10 millions de dollars de jalons de recherche.
Activité sur les actions : 76,4 millions d’actions en circulation après émissions ATM ; les capitaux propres des actionnaires ont chuté à 447,6 millions de dollars contre 527,0 millions en raison d’un déficit accru.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) – Highlights des 10-Q für das zweite Fiskalquartal 2025

Umsatzanstieg: Der Gesamtumsatz im zweiten Quartal stieg auf 44,1 Millionen US-Dollar (plus 264 % im Jahresvergleich), angetrieben durch eine 30 Millionen US-Dollar Lizenzgebühr von Sanofi sowie höhere Kooperationsumsätze mit Sanofi, Gilead und Pfizer.
Beschleunigte Betriebskosten: Die F&E-Ausgaben stiegen im Jahresvergleich um 60 % auf 78,1 Millionen US-Dollar, da das Unternehmen klinische Programme (NX-5948, NX-2127, NX-1607) und DAC-Entdeckungsarbeiten vorantrieb; die allgemeinen Verwaltungsaufwendungen stiegen um 22 % auf 14,3 Millionen US-Dollar.
Verlust im Quartal leicht verringert: Der Nettoverlust betrug 43,5 Millionen US-Dollar (-0,52 US-Dollar je Aktie) gegenüber 44,5 Millionen (-0,71) im Vorjahr, begünstigt durch die einmalige Lizenzzahlung und eine höhere Aktienanzahl. Für den Sechsmonatszeitraum weitete sich der Verlust jedoch auf 99,8 Millionen US-Dollar aus.
Cash-Runway: Zum 31. Mai 2025 beliefen sich Barmittel, Zahlungsmitteläquivalente und handelbare Wertpapiere auf 485,8 Millionen US-Dollar, gegenüber 609,6 Millionen zum Geschäftsjahresende. Der operative Cash-Burn erreichte in der ersten Jahreshälfte 124,2 Millionen. Das Management geht davon aus, dass die vorhandene Liquidität die Geschäftstätigkeit mindestens 12 Monate finanziert.
Kooperationsdynamik: • Gilead verlängerte die Forschungsphase um zwei Jahre und löste eine Zahlung von 15 Millionen US-Dollar aus.
• Sanofi übte zwei Ziel-Lizenzoptionen aus und brachte 30 Millionen US-Dollar ein.
• Die Zusammenarbeit mit Pfizer erzielte bisher 10 Millionen US-Dollar an Forschungsmeilensteinen.
Aktienaktivität: Nach ATM-Emissionen sind 76,4 Millionen Aktien ausstehend; das Eigenkapital der Aktionäre sank aufgrund eines höheren Defizits von 527,0 Millionen auf 447,6 Millionen US-Dollar.

Insgesamt monetarisiert Nurix weiterhin seine DEL-AI-Plattform durch Partnerzahlungen, während die interne F&E beschleunigt wird, was zu einem höheren Cash-Burn und anhaltenden Verlusten führt.

07/09/2025 - 04:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jung Hyunsu

(Last)

(First)

(Middle)

C/O HYPERION DEFI, INC.

23461 SOUTH POINT DRIVE, SUITE 390

(Street)

LAGUNA HILLS

92653

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HYPERION DEFI, INC. [ HYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Investment Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.0001	06/17/2025		A		500,000⁽¹⁾	A	$0	500,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These grants vested in full immediately effective with Mr. Jung's start date with the Company on June 17, 2025.

	/s/ Hyunsu Jung	07/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How much cash does Nurix Therapeutics (NRIX) have after Q2 2025?

Nurix reported $485.8 million in cash, cash equivalents and marketable securities as of 31 May 2025.

What drove the 264% revenue increase for NRIX in Q2 2025?

Revenue growth was primarily due to a $30 million license fee from Sanofi and higher ongoing collaboration revenue.

What is Nurix’s current cash burn rate?

Operating activities used $124.2 million in cash over six months, implying roughly $20 million per month.

Did Nurix post a profit in Q2 2025?

No. The company recorded a net loss of $43.5 million (-$0.52 per share) for the quarter.

How many shares of NRIX are outstanding?

As of 31 May 2025, Nurix had 76,449,355 common shares outstanding.

What milestones could NRIX receive from its partners?

Potential future milestone payments total up to ~$1.8 billion from Gilead, ~$949 million from Sanofi, and ~$3.4 billion from Pfizer, plus royalties.

[Form 4] Eyenovia, Inc. Insider Trading Activity

Insights

FAQ

How much cash does Nurix Therapeutics (NRIX) have after Q2 2025?

What drove the 264% revenue increase for NRIX in Q2 2025?

What is Nurix’s current cash burn rate?

Did Nurix post a profit in Q2 2025?

How many shares of NRIX are outstanding?

What milestones could NRIX receive from its partners?

NASDAQ:EYEN

EYEN Rankings

EYEN Latest News

EYEN Latest SEC Filings

EYEN Stock Data

Trending News

[Form 4] Eyenovia, Inc. Insider Trading Activity

Insights

Biotechnology Equity Analyst neutral

Life-Sciences Portfolio Manager neutral

FAQ

How much cash does Nurix Therapeutics (NRIX) have after Q2 2025?

What drove the 264% revenue increase for NRIX in Q2 2025?

What is Nurix’s current cash burn rate?

Did Nurix post a profit in Q2 2025?

How many shares of NRIX are outstanding?

What milestones could NRIX receive from its partners?

NASDAQ:EYEN

EYEN Rankings

EYEN Latest News

EYEN Latest SEC Filings

EYEN Stock Data